Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

Published:2019-11-01 Issue:11 Volume:5 Page:1556
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Schmid Peter¹²,Zaiss Matthias³,Harper-Wynne Catherine⁴,Ferreira Marta⁵,Dubey Sidharth⁶,Chan Stephen⁷,Makris Andreas⁸,Nemsadze Gia⁹,Brunt Adrian M.¹⁰,Kuemmel Sherko¹¹,Ruiz Isabel¹²,Perelló Antonia¹³,Kendall Anne¹⁴,Brown Janet¹⁵,Kristeleit Hartmut¹⁶,Conibear John²,Saura Cristina¹⁷,Grenier Julien¹⁸,Máhr Károly¹⁹,Schenker Michael²⁰,Sohn Joohyuk²¹,Lee Keun Seok²²,Shepherd Christopher J.²³,Oelmann Elisabeth²³,Sarker Shah-Jalal¹,Prendergast Aaron¹,Marosics Patricia¹,Moosa Atiyyah¹,Lawrence Cheryl¹,Coetzee Carike¹,Mousa Kelly¹,Cortés Javier¹⁷²⁴²⁵

Affiliation:

1. Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom

2. Oncology–Clinical, Barts Health National Health Service Trust, London, United Kingdom

3. Praxis fuer Interdisziplinaere Onkologie, Freiburg, Germany

4. Kent Oncology Centre, Maidstone and Tunbridge Wells National Health Service Trust, Tunbridge Wells, United Kingdom

5. Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal

6. Oncology, Derriford Hospital, Plymouth Hospitals National Health System Trust, Plymouth, United Kingdom

7. Oncology–Clinical, Nottingham University Hospitals National Health System Trust, Nottingham, United Kingdom

8. Mount Vernon Cancer Centre, East & North Herts National Health System Trust, London, United Kingdom

9. Institute of Clinical Oncology, Tbilisi, Republic of Georgia

10. Cancer Centre, University Hospitals of North Midlands National Health System Trust, Stoke-on-Trent, United Kingdom

11. Kliniken Essen-Mitte, Essen, Germany

12. Hospital Universitario Sant Joan De Reus, Tarragona, Spain

13. Hospital Son Espases, Palma, Spain

14. Cancer Services, Great Western Hospitals National Health System Foundation Trust, Swindon, United Kingdom

15. Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, United Kingdom

16. Medical Oncology, Queen Elizabeth Hospital, Woolwich, Lewisham and Greenwich National Health System Trust, London, United Kingdom

17. Vall d’Hebron Institute of Oncology, SOLTI Breast Cancer Research Group, Vall d’Hebron University Hospital, Barcelona, Spain

18. Institut Sainte Catherine, Avignon, France

19. Zala County Hospital, Zalaegerszeg, Hungary

20. Sf Nectarie Oncology Center Societate cu Raspundere Limitata, Craiova, Dolj, Romania

21. Yonsei University Health System, Seoul, Republic of Korea

22. National Cancer Center, Goyang-si Gyeonggi-do, Republic of Korea

23. Oncology Translational Medicine Unit, Innovative Medicines and Early Drug Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom

24. Ramon y Cajal University Hospital, Madrid, Spain

25. Baselga Oncology Institute, Institute of Oncology, QuironGroup, Madrid, Spain

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2749178/jamaoncology_schmid_2019_oi_190056_1607525610.29516.pdf

Reference27 articles.

1. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.;Miller;J Clin Oncol,2011

2. Comprehensive molecular portraits of human breast tumours.;Cancer Genome Atlas Network;Nature,2012

3. The landscape of cancer genes and mutational processes in breast cancer.;Stephens;Nature,2012

4. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.;Thorpe;Nat Rev Cancer,2015

5. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients.;van der Hage;Br J Cancer,2004

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer;Journal of Clinical Medicine;2024-06-20

2. Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer;Cancers;2024-06-18

3. Systemic Therapy in Breast Cancer;American Society of Clinical Oncology Educational Book;2024-06-01

4. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review;Breast Cancer Research;2024-05-22

5. Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort;Breast Cancer Research and Treatment;2024-05-04